Stematix, Inc. Enters into Negotiations with Greek Venture Capital Fund G.I.V.E. – TANEO for Funding of Stem Cell Banks and Therapy Clinics in Greece

HOUSTON--(BUSINESS WIRE)--StematixTM, Inc., a regenerative medicine technology and solutions provider positioned to accelerate safe and effective global use of stem cell therapies, announced today that it has entered into financing negotiations with a Greek venture capital fund, GloCal Investment Ventures Enterprise (G.I.V.E.), funded in part by a Greek government backed fund of funds (TANEO) and managed by GloCal Systems Management (GSM). GSM’s CEO, a Greek-American, Dr. James C. Seferis, has had a distinguished career in academia and in nurturing new technology industry initiatives.